192 related articles for article (PubMed ID: 36137710)
1. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Pike KG; Hunt TA; Barlaam B; Benstead D; Cadogan E; Chen K; Cook CR; Colclough N; Deng C; Durant ST; Eatherton A; Goldberg K; Johnström P; Liu L; Liu Z; Nissink JWM; Pang C; Pass M; Robb GR; Roberts C; Schou M; Steward O; Sykes A; Yan Y; Zhai B; Zheng L
J Med Chem; 2024 Feb; 67(4):3090-3111. PubMed ID: 38306388
[TBL] [Abstract][Full Text] [Related]
3. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Parrish KE; Pokorny J; Mittapalli RK; Bakken K; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2015 Nov; 355(2):264-71. PubMed ID: 26354993
[TBL] [Abstract][Full Text] [Related]
4. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
[TBL] [Abstract][Full Text] [Related]
5. Murine Central Nervous System and Bone Marrow Distribution of the Aurora A Kinase Inhibitor Alisertib: Pharmacokinetics and Exposure at the Sites of Efficacy and Toxicity.
Oh JH; Power EA; Zhang W; Daniels DJ; Elmquist WF
J Pharmacol Exp Ther; 2022 Oct; 383(1):44-55. PubMed ID: 36279392
[TBL] [Abstract][Full Text] [Related]
6. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
[TBL] [Abstract][Full Text] [Related]
7. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
[TBL] [Abstract][Full Text] [Related]
8. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
[TBL] [Abstract][Full Text] [Related]
9. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
[TBL] [Abstract][Full Text] [Related]
10. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
Talele S; Zhang W; Burgenske DM; Kim M; Mohammad AS; Dragojevic S; Gupta SK; Bindra RS; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2021 Dec; 379(3):343-357. PubMed ID: 34556535
[TBL] [Abstract][Full Text] [Related]
11. Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases.
Talele S; Zhang W; Oh JH; Burgenske DM; Mladek AC; Dragojevic S; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2022 Jun; 381(3):217-228. PubMed ID: 35370138
[TBL] [Abstract][Full Text] [Related]
12. ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis.
Tew BY; Kalfa AJ; Yang Z; Hurth KM; Simon T; Abnoosian E; Durant ST; Hamerlik P; Salhia B
Clin Cancer Res; 2023 Nov; 29(21):4492-4503. PubMed ID: 37585496
[TBL] [Abstract][Full Text] [Related]
13. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
14. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal S; Mittapalli RK; Zellmer DM; Gallardo JL; Donelson R; Seiler C; Decker SA; Santacruz KS; Pokorny JL; Sarkaria JN; Elmquist WF; Ohlfest JR
Mol Cancer Ther; 2012 Oct; 11(10):2183-92. PubMed ID: 22891038
[TBL] [Abstract][Full Text] [Related]
15. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
Oberoi RK; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Dec; 347(3):755-64. PubMed ID: 24113148
[TBL] [Abstract][Full Text] [Related]
18. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Minocha M; Khurana V; Qin B; Pal D; Mitra AK
Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
[TBL] [Abstract][Full Text] [Related]
19. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
20. Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and
Kim M; Laramy JK; Mohammad AS; Talele S; Fisher J; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Apr; 47(4):393-404. PubMed ID: 30705084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
